"
Team:BIOSINT Mexico/symposium
From 2014.igem.org
| Line 30: | Line 30: | ||
<div class="texto1"> | <div class="texto1"> | ||
<h1> INTERNATIONAL SYSTEMS AND SYNTHETIC BIOLOGY SYMPOSIUM </h1> | <h1> INTERNATIONAL SYSTEMS AND SYNTHETIC BIOLOGY SYMPOSIUM </h1> | ||
| - | <p> The First International Systems and Synthetic Biology Symposium took place in Tecnológico de Monterrey Campus Querétaro on April 25th, 2014. The speakers that headed the agenda were:</p> | + | <p> The First International Systems and Synthetic Biology Symposium took place in Tecnológico de Monterrey Campus Querétaro on April 25th, 2014. The speakers that headed the agenda were:<br/> |
| + | PhD. J. Rubén Morones who presented “Approaches to Engineer and Design Antimicrobial Therapeutics” in which he explained three engineering approaches to resolve some of the challenges in antibiotic development. The first involves exploring potentiation of current antibiotics using novel and naturally existing therapeutic adjuvants (such as silver and supplementary metallic micronutrients). The second includes the work in progress to develop novel drug delivery systems, using Nanotechnology and Synthetic Biology. Finally, the third addresses the commitment to discover novel antimicrobial molecules and therapies. </p> | ||
</body> | </body> | ||
</html> | </html> | ||
Revision as of 01:02, 2 October 2014
INTERNATIONAL SYSTEMS AND SYNTHETIC BIOLOGY SYMPOSIUM
The First International Systems and Synthetic Biology Symposium took place in Tecnológico de Monterrey Campus Querétaro on April 25th, 2014. The speakers that headed the agenda were:
PhD. J. Rubén Morones who presented “Approaches to Engineer and Design Antimicrobial Therapeutics” in which he explained three engineering approaches to resolve some of the challenges in antibiotic development. The first involves exploring potentiation of current antibiotics using novel and naturally existing therapeutic adjuvants (such as silver and supplementary metallic micronutrients). The second includes the work in progress to develop novel drug delivery systems, using Nanotechnology and Synthetic Biology. Finally, the third addresses the commitment to discover novel antimicrobial molecules and therapies.
